- Home
- SGRY vs ZLAB Comparison
SGRY vs ZLAB Comparison
Compare SGRY & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGRY | ZLAB |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SGRY | ZLAB |
|---|---|---|
| Price | $15.48 | $18.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $27.00 | ★ $53.52 |
| AVG Volume (30 Days) | ★ 1.3M | 787.1K |
| Earning Date | 03-02-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,288,100,000.00 | $441,629,000.00 |
| Revenue This Year | $7.76 | $26.16 |
| Revenue Next Year | $8.16 | $30.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 10.14 | ★ 24.14 |
| 52 Week Low | $14.94 | $16.82 |
| 52 Week High | $26.16 | $44.34 |
Technical Indicators
Market Signals| Indicator | SGRY | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 47.19 |
| Support Level | $15.29 | $18.40 |
| Resistance Level | $16.44 | $19.14 |
| Average True Range (ATR) | 0.54 | 0.60 |
| MACD | 0.06 | 0.19 |
| Stochastic Oscillator | 21.26 | 48.68 |
Price Performance
Historical ComparisonAbout SGRY Surgery Partners Inc.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.